Company Developing PAH Therapy Secures $34M in Funding

  • Company Developing PAH Therapy Secures $34M in Funding

    Posted by Community Member on September 10, 2018 at 6:37 pm

    PhaseBio Pharmaceuticals has secured $34 million in financing to advance the clinical development of PB1046, a potential treatment for PAH, among others.

    Click here to read more about this story.

    What are your thoughts on this news?

    replied 1 Member · 0 Replies
  • 0 Replies

Sorry, there were no replies found.

Log in to reply.